Article
Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.
Internal medicine (Tokyo, Japan) - 1 Oct 2018
Ishikawa Toru, Imai Michitaka, Owaki Takashi, Sato Hiroki, Nozawa Yujiro, Sano Tomoe, Iwanaga Akito, Seki Keiichi, Honma Terasu, Yoshida Toshiaki
Abstract excerpt
The optimum retreatment strategy for chronic hepatitis C virus (HCV) patients who failed directly-acting antiviral agents (DAA)-based therapy is unknown. We herein report the outcomes of an HCV genotype (GT) 2a-infected patient with virologic failure following treatment with sofosbuvir plus ribavirin (SOF+RBV) who was successfully retreated with ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r+RBV).
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.